Revenue: As of FY2026 Q1, the actual value is USD 50.16 M.

EPS: As of FY2026 Q1, the actual value is USD -0.2.

EBIT: As of FY2026 Q1, the actual value is USD -8.986 M.

Revenue

Total revenue for Q1 2026 was $50.2 million, exceeding the company’s guidance range of $48 million to $49 million, though this represents a -1% year-over-year change compared to $50.9 million in Q1 2025. The majority of revenue was derived from recurring subscriptions . Telehealth revenue, net, for Q1 2026 was $50,162,956 .

Profitability

Gross profit for Q1 2026 increased 3% to $44.2 million . Gross margin expanded to 88% in Q1 2026, an increase of approximately 420 basis points compared to 84% in the prior-year period, primarily due to product mix and lower fulfillment costs . The operating loss from continuing operations in Q1 2026 was - $8,929,072, compared to - $1,181,717 in Q1 2025 . Net loss from continuing operations for Q1 2026 was - $8,872,596, compared to - $1,645,355 in Q1 2025 . Adjusted EBITDA for Q1 2026 was a loss of - $4.5 million, compared with an adjusted EBITDA of $3.7 million in the prior-year period, primarily reflecting a planned increase in patient acquisition spend .

Operating Costs

Cost of telehealth revenue in Q1 2026 was $5,925,499, down from $8,136,462 in Q1 2025 . Selling and marketing expenses increased 34% to $29.9 million in Q1 2026, reflecting strategic, front-loaded patient acquisition investments . General and administrative expenses were $15,176,355 in Q1 2026, up from $14,340,151 in Q1 2025 . Other operating expenses were $3,179,946, up from $2,389,536 in Q1 2025 . Customer service expenses were $3,139,305, up from $3,071,494 in Q1 2025 . Development costs were $1,796,063, down from $1,859,049 in Q1 2025 . Total expenses for Q1 2026 were $53,166,529, up from $43,933,154 in Q1 2025 .

Cash Flow and Balance Sheet

Cash at quarter end on March 31, 2026, was $34.5 million, specifically $34,478,137, compared to $36,786,318 at December 31, 2025 . The company had no debt at quarter end . Net cash provided by operating activities in Q1 2026 was $444,624, compared to $3,068,387 in Q1 2025 . Net cash used in investing activities was - $2,056,762 in Q1 2026, compared to - $2,867,338 in Q1 2025 . Net cash used in financing activities was - $696,043 in Q1 2026, compared to - $812,563 in Q1 2025 . Total current assets on March 31, 2026, were $51,697,046, compared to $51,831,465 at December 31, 2025 . Total liabilities on March 31, 2026, were $55,087,822, compared to $47,254,739 at December 31, 2025 .

Operational Metrics

LifeMD added over 42,000 net telehealth subscribers in Q1 2026, marking the largest quarterly net addition in the company’s history . Total active subscribers at the end of Q1 2026 exceeded 365,000, an increase of approximately 26% year-over-year . The company reported record sign-ups for GLP-1 patients . Weight management new-patient revenues grew approximately 120% versus the fourth quarter of 2025, with just under 100,000 subscribers in the weight management program in Q1 2026 . Women’s health patient sign-ups showed 657% quarter-over-quarter growth, accompanied by an approximately 70% reduction in customer acquisition costs .

Outlook / Guidance

LifeMD anticipates Q2 2026 revenue to be in the range of $47 million to $50 million, with adjusted EBITDA projected between - $2 million and positive $1 million . For the full year 2026, the company reaffirms its guidance for revenue of $220 million to $230 million, representing 13% to 19% year-over-year growth, and adjusted EBITDA in the range of $12 million to $17 million . Additionally, annualized run-rate revenue is expected to surpass $250 million and annualized run-rate adjusted EBITDA to exceed $25 million by Q4 2026 .